S-1: Salarius Pharmaceuticals Announces Merger with Decoy Therapeutics, Aims for Peptide Conjugate Leadership

Salarius Pharmaceuticals will merge with Decoy Therapeutics in a stock-for-stock transaction, shifting focus to peptide conjugate therapeutics.

Summary

• Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company, has entered into a merger agreement with Decoy Therapeutics, a pre-clinical stage biotechnology company.
• The merger is structured as a stock-for-stock transaction, with Decoy stockholders expected to own approximately 85.9% of the combined company, subject to adjustments based on cash balances at closing.
• The combined company will focus on developing peptide conjugate therapeutics, leveraging Decoys IMP 3 ACT platform and Salarius SP-3164 compound.
• The merger is contingent upon a minimum of $6.0 million in proceeds from a future offering and the continued listing of Salarius common stock on Nasdaq.
• Salarius has agreed to issue shares of common stock and Series A preferred stock to Decoy stockholders, with the preferred stock convertible into common stock upon stockholder approval.
• The combined company will continue to support MD Anderson Cancer Centers ongoing clinical trial evaluating seclidemstat (SP-2577) in combination with azacytidine for certain blood disorders.
• Salarius has terminated its ongoing Phase 1/2 clinical trial evaluating SP-2577 for Ewing sarcoma to conserve cash.
• Salarius has entered into a Warrant Cancellation Agreement with an investor, paying $350,000 in cash to cancel a warrant to purchase 454,546 shares of its common stock.
• Salarius has entered into a securities purchase agreement with C/M Capital Master Fund, LP, pursuant to which Salarius has the right, but not the obligation, to sell up to $10 million of newly issued shares of Salarius common stock.
• The combined company plans to integrate Salarius assets, particularly the proprietary compound SP-3164, to expand its opportunities in creating a novel class of peptide conjugates called peptide-based proteolysis targeting chimeras (PPROTACs).

Sentiment

Score: 4

Explanation: The document presents a mix of positive and negative aspects. The merger and focus on peptide conjugates are positive, but the financial challenges, termination of a clinical trial, and potential dilution are concerning. The overall sentiment is cautiously optimistic but with significant risks.

Positives

• The merger combines Salarius's small molecule assets with Decoy's peptide conjugate technology, potentially creating synergies.
• The combined company will have a broader product portfolio, potentially enhancing its ability to raise capital.
• Decoy's management team and established life science investors are expected to bring expertise to the combined company.
• The merger is expected to expand Decoy's focus to include exploratory research on P-PROTACs for metastatic colorectal cancer.

Negatives

• Salarius terminated its ongoing Phase 1/2 clinical trial evaluating SP-2577 for Ewing sarcoma to conserve cash.
• The merger is contingent upon a minimum of $6.0 million in proceeds from a future offering, which may not be achieved.
• Salarius stockholders will experience significant dilution as a result of the merger and the Qualified Financing.
• The combined company may not be able to maintain its Nasdaq listing following the Merger Closing.

Risks

• The merger may be completed even if material adverse changes occur prior to closing.
• The exchange ratio is adjustable based on cash balances, which could result in Salarius stockholders owning less of the combined company.
• The combined company may not realize the full strategic and financial benefits of the merger.
• The combined company will need to raise additional capital, which may cause dilution or restrict operations.
• The combined company may not be able to protect its intellectual property rights.
• The combined company may never earn a profit.
• Decoy's financial condition raises substantial doubt regarding its ability to continue as a going concern.
• Decoy has never generated revenue from product sales and all of Decoy's product candidates are currently in the preclinical stage.

Future Outlook

The combined company plans to integrate Salarius assets, particularly the proprietary compound SP-3164, to expand its opportunities in creating a novel class of peptide conjugates called peptide-based proteolysis targeting chimeras (PPROTACs).

Management Comments

• Salarius board of directors believed that, as a result of arms length negotiations with Decoy, Salarius and its management team negotiated the most favorable implied value and equity split for its stockholders that Decoy was willing to agree to.
• The Salarius board of directors also believed, after a thorough review of strategic alternatives and discussions with Salarius senior management, its financial advisors and legal counsel, that the Merger is more favorable to its stockholders than the potential value that might have resulted from other strategic options available to Salarius, which would likely be a liquidation of Salarius and the distribution of any available cash if the Merger is not consummated.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards combining different therapeutic modalities to address complex diseases. Peptide conjugates are an emerging class of drugs with significant potential.

Comparison to Industry Standards

• The peptide conjugate drug class is extremely modular and flexible, making it applicable to a wide range of human disease states and medical indications, similar to the broad applicability of antibody-drug conjugates (ADCs).
• Decoy's approach to peptide conjugate development, leveraging machine learning and artificial intelligence, is similar to other companies that are using AI to accelerate drug discovery.
• The combined company's focus on P-PROTACs is a novel approach, combining the advantages of peptides with targeted protein degradation, which is a growing area of interest in the pharmaceutical industry.
• The combined company's approach to drug development is similar to other companies that are combining small molecule assets with peptide conjugate technology.

Management Changes

Related Party Transactions

• Dr. McVicar, a member of the Salarius board of directors, serves as a consultant to DeuteRx and is a consultant to an affiliate of DeuteRx. The Purchased Assets were purchased for an aggregate purchase price of $1,500,000 and the delivery of 40,000 shares of Salarius common stock. Salarius also agreed to pay to DeuteRx (i) milestone payments upon the occurrence of certain events and (ii) royalty payments.

Stakeholder Impact

• Salarius stockholders will experience significant dilution as a result of the merger and the Qualified Financing.
• Decoy stockholders will gain a majority ownership in the combined company.
• Employees of both companies may experience changes in their roles and responsibilities.
• Customers and partners of both companies may be affected by the integration of the two businesses.

Next Steps

• The combined company will seek stockholder approval for the conversion of the preferred stock to be issued at Merger Closing into shares of Common Stock.
• The combined company will seek stockholder approval for a new equity incentive plan.
• The combined company will conduct a thorough review of the seclidemstat (SP-2577) program.
• The combined company will integrate Salarius assets, particularly the proprietary compound SP-3164, to expand its opportunities in creating a novel class of peptide conjugates called peptide-based proteolysis targeting chimeras (PPROTACs).

Key Dates

Keywords

Merger, Peptide Conjugates, Biopharmaceutical, Oncology, Infectious Diseases, SP-3164, SP-2577, P-PROTACs, Drug Development, Clinical Trials